Rangeley Capital LLC Grows Stock Holdings in Janux Therapeutics, Inc. $JANX

Rangeley Capital LLC grew its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 382.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 122,500 shares of the company’s stock after purchasing an additional 97,086 shares during the period. Janux Therapeutics comprises 1.6% of Rangeley Capital LLC’s investment portfolio, making the stock its 21st largest holding. Rangeley Capital LLC’s holdings in Janux Therapeutics were worth $1,703,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. State Street Corp lifted its holdings in shares of Janux Therapeutics by 103.8% during the 4th quarter. State Street Corp now owns 3,853,951 shares of the company’s stock valued at $53,185,000 after acquiring an additional 1,962,486 shares in the last quarter. Prosight Management LP boosted its position in Janux Therapeutics by 176.5% during the 4th quarter. Prosight Management LP now owns 2,392,523 shares of the company’s stock worth $33,017,000 after purchasing an additional 1,527,173 shares during the period. Wellington Management Group LLP increased its holdings in Janux Therapeutics by 129.5% in the 4th quarter. Wellington Management Group LLP now owns 1,610,186 shares of the company’s stock valued at $22,221,000 after purchasing an additional 908,582 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Janux Therapeutics in the 4th quarter valued at $12,221,000. Finally, Alyeska Investment Group L.P. raised its position in Janux Therapeutics by 206.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 1,301,089 shares of the company’s stock valued at $17,955,000 after purchasing an additional 876,244 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JANX shares. Wall Street Zen raised Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, April 5th. Truist Financial reiterated a “buy” rating and set a $26.00 target price (down from $80.00) on shares of Janux Therapeutics in a report on Thursday, June 25th. UBS Group downgraded Janux Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $57.00 to $15.00 in a report on Wednesday, April 15th. Guggenheim decreased their price target on Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating for the company in a report on Friday, May 8th. Finally, Barclays downgraded shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and lowered their price objective for the company from $29.00 to $14.00 in a research report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Janux Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $38.08.

Insider Buying and Selling

In other news, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $14.17, for a total transaction of $28,878.46. Following the completion of the sale, the vice president owned 32,270 shares of the company’s stock, valued at approximately $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Janeen Noel Doyle sold 4,059 shares of the company’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider directly owned 75,941 shares in the company, valued at $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $15.33 on Monday. Janux Therapeutics, Inc. has a 1-year low of $12.12 and a 1-year high of $35.34. The company has a market capitalization of $934.82 million, a PE ratio of -8.33 and a beta of 2.52. The business has a 50-day moving average of $14.81 and a 200-day moving average of $14.33.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.13. The business had revenue of $3.73 million during the quarter, compared to analyst estimates of $4.36 million. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.7 earnings per share for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.